1 omnia, nausea, constipation, sleepiness, and indigestion.

2 toms, and longer in patients presenting with indigestion (0.71, 0.56-0.89; p=0.0033), back pain (0.77

3 h system intervals were likewise longer with indigestion (0.74, 0.58-0.95; p=0.0018), back pain (0.76

4 rom upper gastrointestinal side effects like indigestion (65.8%), heartburn (78.3%), nausea (48.8%),

5 s, significantly greater symptoms of reflux, indigestion and abdominal pain were reported.

6 ed in the Reflux (heartburn, regurgitation), Indigestion, and Abdominal pain domains of the GSRS, bot

7 herbal tea used for soothing stomach cramps, indigestion, and nausea.

8   Stress was positively related to diarrhea, indigestion, and reflux syndromes and with abdominal pai

9  that RD primarily improves symptoms such as indigestion, constipation, fatigue, polyuria, and depres

10        The severity of diarrhea, reflux, and indigestion decreased.

11 f GI symptoms, particularly in patients with indigestion, diabetes, on steroids, and in patients conv

12  supported 6 multi-item HRQOL scales: reflux/indigestion, diarrhea, constipation, pain, emotional wel

13               The GFD group also had reduced indigestion (P = .006), reflux (P = .05), and anxiety (P

14  = 0.0342), abdominal pain (P = 0.0058), and indigestion (P = 0.0003) syndromes were lower after gala

15 ommon adverse event with both treatments was indigestion-reflux (eight participants, 208 participant-

16 ointestinal symptom burden (P=0.033), and an indigestion score that correlated with peak superior mes

17 e most common nonserious adverse events were indigestion/stomach upset (64.9% for metformin and 40.6%

18                                              Indigestion subscore (LMAH-C 2.9 +/- 1.5 vs LNF 3.7 +/-

19                                          The indigestion subscore of the Gastrointestinal Symptom Rat

20 in the Gastrointestinal Symptom Rating Scale indigestion syndrome dimension versus MMF patients.